ClinicalTrials.gg
Active, not recruitingNCT04858776DEXTERITY-SCIUpdated Jun 25, 2026

Perivenous Dexamethasone Therapy: Examining Reduction of Inflammation After Thrombus Removal to Yield Benefit in Subacute and Chronic Iliofemoral DVT

A Phase 2 interventional study of Perivascular dexamethasone and Perivascular sham in Iliofemoral; Thrombosis, sponsored by Mercator MedSystems, Inc.. Active, not recruiting at 15 sites in 3 countries. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Mercator MedSystems, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 303 studies in Thrombosis with a site in United States — 43 open to participants now, 49 under way, 5 of them phase 3. Thrombosis · United States.

Planned enrollment
97th of 188
60 · median 67
Started
2022
with 8 others
Phase 2
38 of 303
5 open now
Primary completion
2025-08
later than 4 of 48 live
Registered
243rd of 303
by date

Among the 303 studies in Thrombosis with a site in United States, this one is the 97th largest by planned enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2022, is one of 38 in phase 2, reaches primary completion later than 4 of the 48 other live ones, and was the 243rd registered.

Thrombosis

956 studies on the registry are indexed under Thrombosis; 172 are open to participants now.

Browse Thrombosis studies →

Open to participants now

43 of the 303 studies in Thrombosis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 128 Thrombosis studies recruiting now, 80 (63%) set no upper age limit and 17 (13%) stop at 75 or younger; 21 take children under 18; 21 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Thrombosis with a site in United States, or all of them as a file.
02

Study summary

This is a study of a medical procedure that utilizes a commercially available catheter (the Bullfrog® Micro-Infusion Device) to locally deliver a commercially available anti-inflammatory drug (dexamethasone sodium phosphate injection) around the deep veins after DVT recanalization, where DVT symptoms were present for at least 14 days and no more than 60 days prior to recanalization. The goal of the study is to see if local anti-inflammation helps prevent re-thrombosis of the blood vessel and improvement in symptoms for up to 24 months after the initial DVT recanalization procedure.

03

Conditions studied

  • Iliofemoral; Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of signed and dated form prior to receiving any non-standard of care, protocol-specific procedures.
  2. Stated willingness to comply with all study procedures including completion of questionnaires and follow-up visits and availability for the duration of the study.
  3. Male or female, aged 18 to 89 years.
  4. For females of : negative pregnancy test ≤7 days before the procedure, use of highly effective for at least 1 month prior to screening, and agreement to use such a method during study participation.
  5. Negative COVID-19 test result within 5 days prior to procedure or evidence of COVID-19 vaccine or booster within past 12 months.
  6. Onset of DVT symptoms 14 to 60 days prior to intervention in the study limb with need for stenting of the iliofemoral segment.
  7. Ability to take oral medication and be willing to adhere to the prescribed anti-coagulant regimen.
  8. Prescription for at least 14 days low molecular weight heparin followed by therapeutic anticoagulant of investigator's choice for 12-month minimum as part of post-interventional medication regimen.
  9. Minimum of 30 days of prescribed antiplatelet agent (aspirin or P2Y12 inhibitor).
  10. Hemodynamically significant DVT (>50% area obstruction) spanning at least (a) the iliofemoral and common femoral veins or (b) the common femoral vein with extension into the femoral vein and/or profunda vein. Extent of thrombus in the popliteal and calf veins is allowed.
  11. Successful recanalization of the target vein with at least one patent inflow vein (femoral or profunda).

Exclusion criteria

Exclusion Criteria:

  1. Current enrollment in another non-registry clinical study of systemic drug therapy or another device study that has not completed its primary endpoint, including prior enrollment in this study. Concurrent enrollment in registry studies of approved devices or drugs are acceptable.
  2. Lack of capability of understanding the nature, significance and implications of the clinical trial.
  3. > 40 kg/m2.
  4. Non-ambulatory status prior to DVT occurrence.
  5. In the target vein segment: previously treated symptomatic DVT within the previous 12 months.
  6. In the contralateral (non-study) leg: symptomatic DVT that, in the opinion of the operating physician, will require surgery in the following 30 days.
  7. Limb-threatening circulatory compromise with ankle-brachial index \<0.4, absolute ankle pressure \<50 mmHg or absolute toe pressure \<30 mmHg.
  8. Pulmonary embolism (PE) defined as either massive (Systolic blood pressure \< 90 mmHg and/or patient on IV vasoactive medication to support blood pressure), or intermediate high-risk PE, as defined by the European Society Guideline on management of PE. Low-risk PE and/or intermediate low-risk PE can be enrolled.
  9. Inability to tolerate contemporary venous intervention procedure due to severe dyspnea or acute systemic illness.
  10. Allergy, , or thrombocytopenia from heparin, Recombinant tissue plasminogen activator (rtPA), dexamethasone sodium phosphate or iodinated contrast, except for mild-moderate contrast allergies for which pre-medication can be used.
  11. History of, or active heparin-induced thrombocytopenia (HIT).
  12. \< 9.0 mg/dl, > 1.6 before starting anticoagulation, or \< 100,000/ml. Moderate renal impairment in diabetic patients (estimated \< 60 ml/min) or severe renal impairment in non-diabetic patients (estimated glomerular filtration rate \< 30 ml/min).
  13. Active bleeding, recent (\< 3 mo) GI bleeding, severe liver dysfunction, bleeding diathesis.
  14. Recent (\< 3 mo) internal eye surgery or haemorrhagic retinopathy; recent (\< 10 days) major surgery, cataract surgery, trauma, cardiopulmonary resuscitation, obstetrical delivery, or other invasive procedure.
  15. History of hemorrhagic stroke or intracranial/intraspinal bleed, tumor, vascular malformation, aneurysm.
  16. Active cancer with a of \<2 years.
  17. Severe hypertension on repeated readings (systolic blood pressure > 180 mmHg or diastolic blood pressure > 105 mmHg). This can be treated, and blood pressure must be stable before venous access is obtained (systolic blood pressure \<140 mmHg).
  18. Pregnant or breastfeeding.
  19. Life expectancy \< 2 years.
  20. Thrombus of the inferior vena cava (IVC) extending at least one centimeter above the common iliac confluence.
  21. Inability to obtain venous access.
  22. Inability to recanalize the target vein segment(s).
  23. History of ipsilateral venous stent.
  24. DVT length to be targeted for perivascular drug therapy exceeds 50 cm.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Treatment

    Combination Product: Perivascular dexamethasone

  • Sham comparator
    Control

    Combination Product: Perivascular sham

Interventions

  • Combination productPerivascular dexamethasone

    Dexamethasone delivery around target vein segment(s)

  • Combination productPerivascular sham

    Saline delivery around target vein segment(s)

06

What researchers measure

Primary outcomes

  1. Clinically relevant primary patency

    Freedom from loss of patency with associated symptoms

    Time frame: 6 months

  2. Freedom from major adverse event (MAE)

    Freedom from composite of all-cause death, clinically significant pulmonary embolism, major bleeding, target vessel thrombosis, infection of treatment or insertion site, or AV fistula of treatment site

    Time frame: 30 days

07

Study locations

15 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Aug 2025, 36 months.

Of 22 phase 2 interventional studies under Thrombosis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 56. This study's 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 21, 2021
First posted
Apr 26, 2021
StartActual
Aug 8, 2022
Primary completionActual
Aug 28, 2025
CompletionEst.
May 31, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04858776
Lead sponsor
Mercator MedSystems, Inc.
Responsible party
Sponsor
First posted
Apr 26, 2021
Start date
Aug 8, 2022
Primary completion
Aug 28, 2025
Completion
May 31, 2027 (estimated)
Last update
Jun 25, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion